Vortioxetine has to be reasonably tolerated in children and teens, with manageable side effects, to have any chance of inclusion into treatment for anxiety or depression. This research update gives you the latest on whether vortioxetine might be a viable approach even before we have good efficacy studies. 

We struggle to manage the metabolic impact of antipsychotic medications on the children and teens we treat. Could topiramate be a viable option for our armamentarium of strategies? Read our research update to find out. 

Will your teenaged patients be able to safely make their own decisions when they become adults? This clinical update helps you assess and advise your patients who aren’t ready to care for themselves about how to protect them from harm while trying to preserve their autonomy. 

You probably studied genetic conditions during your training, however, it is easy to miss some of these kids and teens in your clinical practice. Our interview with Dr. Marilyn Jones will help you learn what the more common conditions are, how spot them, and what to do next. 

Everyone has unconscious biases that impact how we care for our patients. This clinical update gives you tools to uncover and set aside implicit biases so that you can offer your patients with T21 or other conditions the opportunities they deserve to live their best lives. 

What do you look for to diagnose Fetal Alcohol Spectrum Disorder (FASD)? Read this interview with Dr. Ira Chasnoff to understand the broad impact of FASD and what to look for in the patient’s history (hint: you usually won’t see facial stigmata).

Lithium is FDA-approved for bipolar disorder in children and adolescents 12 years and up; however, its potential off-label utility is broad, from affective aggression to anorexia nervosa. This clinical update covers how to prescribe lithium for children and adolescents and how to talk with patients and parents about lithium.